Predictors and impacts of hospital readmissions following liver transplantation
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 3
Abstract
While liver transplantation is the definitive therapy for end stage liver disease, it remains a major procedure, with many potential complications. Hospital readmissions after the initial hospitalization for liver transplantation can be associated with adverse outcomes, increased cost, and resource utilization. Our aim was to define the incidence and reasons for hospital readmission after liver transplant and the impact of readmissions on patient outcomes. We retrospectively analyzed 30- and 90-day readmission rates and indications in patients who underwent liver transplant at a large-volume transplant center over a 3-year period. Four hundred seventy-nine adult patients underwent their first liver transplant during the study period. The 30-day readmission rate was 29.6%. Recipient and donor age, etiology of liver disease, biological Model for End-Stage Liver Disease score, and cold ischemia time were similar between patients who were readmitted within 30 days and those who were not readmitted. Readmissions occurred in 25% of patients who were hospitalized prior to liver transplant compared to 30% who were admitted for liver transplant. The most common indications for readmission were infection, severe abdominal pain, and biliary complications. Early discharge from hospital (fewer than 7 days after liver transplant), was not associated with readmission; however, a prolonged hospital stay after liver transplant was associated with an increased risk of readmission (p = 0.04). In conclusion, patients who undergo liver transplant have a high rate of readmission. In our cohort, readmissions were unrelated to pre-existing recipient or donor factors, but were associated with a longer hospital stay after liver transplant.
Authors and Affiliations
Maria Yataco, Alissa Cowell, Waseem David, Andrew Keaveny, C. Taner, Tushar Patel
Keywords
Related Articles
- EP ID EP78576
- DOI 10.5604/16652681.1198805
- Views 136
- Downloads 0
Clinical and basal aspects of anemia during antiviral therapy for hepatitis C
Background and Rationale. Anemia is a major side effect of combination therapy for chronic hepatitis C. In this study, severity, potential risk factors for and potential underlying mechanisms of anemia were evaluated. Pa...
How to screen NAFLD patients for diabetes?
Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico
Background and aim. To identify the geographic distribution of hepatitis C virus (HCV) genotypes and HCV RNA viral load in a large number of HCV-infected carriers in Mexico. Methods. Patients with chronic hepatitis C (n...
Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis
Introduction and aim. HCV-infected immigrants contribute to the total prevalence in Canada and other developed nations. Little is known about engagement in care, access to service, and treatment outcomes in recipients of...
Prevalence of hepatitis B seropositivity among Thai workers in screening program before going abroad.